| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| NS+A | 2021-07 | Purchase | 2024-06 |
NSA |
30,625 | 30,032 | 0 | 0 | ||
| FTAI+A | 2020-10 | Purchase | 2024-10 |
FTAIA |
30,000 | 24,921 | 0 | 0 | ||
| AGR | 2017-12 | Purchase | 2024-12 |
AGR |
18,895 | 21,248 | 0 | 0 | ||
| IVR+B | 2021-06 | Purchase | 2024-12 |
IVRB |
30,000 | 30,054 | 0 | 0 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| DEA | 40,782 | 32,842 |
| WFC L | 33,032 | 30,643 |
| TRTX C | 28,732 | 21,660 |
| STWD | 35,563 | 29,084 |
| SHEL | 19,631 | 26,874 |
| PSEC | 37,491 | 22,964 |
| NS A | 0 | 0 |
| KYN | 37,642 | 41,943 |
| IVR B | 0 | 0 |
| GSK | 23,385 | 19,882 |
| GOGL | 1,243 | 9,941 |
| GNL | 44,559 | 18,908 |
| FTAI A | 0 | 0 |
| CVX | 30,572 | 35,771 |
| CODI A | 37,317 | 38,070 |
| BP | 41,781 | 40,923 |
| BMXT | 34,608 | 21,555 |
| AZN | 14,583 | 31,316 |
| ARI | 39,805 | 22,858 |
| AMGM | 24,410 | 37,428 |
| AGR | 0 | 0 |
| AGNCP | 39,990 | 39,424 |
| BIZD | 32,670 | 33,260 |
| GNK | 34,922 | 34,850 |
| ALE | 29,182 | 31,486 |
| EQNR | 12,174 | 15,399 |
| VZ | 27,530 | 23,438 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative expenses | 1,272 | 1,272 | 0 | 0 |